Abzena (Cambridge) Ltd

Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO.

Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor our strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule. Over the past 20 years, Abzena has helped hundreds of customers ranging from emerging biotechs to the top large pharmaceutical firms achieve their regulatory and clinical milestones. With extensive scientific knowledge and technical expertise, our global teams provide customers with comprehensive support that minimizes risks and moves new medicines forward faster- with greater success. Our global locations include San Diego (CA, USA), Bristol (PA, USA), and Cambridge (UK). Comprehensive biologics & bioconjugate support: Antibodies (mAbs), Antibody Fragments (Fabs), Antibody Drug Conjugates (ADCs), Bispecifics, Radioconjugates, Fusion Proteins, Growth Factors, Recombinant & Conjugate Vaccines, Biosimilars, and Oligo conjugates Services that expedite timelines: Abzena develops and implements fully integrated services and tailored, innovative solutions that are designed to rapidly advance your program to its next milestone. • Lead Discovery, Design and Selection • Robust Analytics, Bioassays and Immunogenicity • Antibody Engineering and Developability • Bioconjugation and Complex Chemistry • Mammalian Cell Line Development • Linker Payload Design and Synthesis • Analytical Method & Formulation Development • Process Development and cGMP Manufacturing • Technology Transfer & Scale-Up • Regulatory Support

• Gastrointestinal Tract
• Neurology
• Autoimmune diseases
• Dermatology
• Oncology
• Central Nervous System
• Dementia
• Metabolic Disorders
• Translational Medicine
• Cardiovascular System
• Biomarkers